CYP2J2 is responsible for the production of 5, 6, 8, 9, 11, 12, 14 and 15-epoxyeicosatrienoic acids, vasodilator and anti-inflammatory substances. It is abundantly expressed in human heart and also present in kidney and vasculature. Carriers of a common polymorphism, the CYP2J2 -50G>T, have reduced expression of CYP2J2 mRNA in the heart.

We conducted a population-based, case-control study to determine whether common genetic variation in CYP2J2 gene was associated with the risk of acute myocardial infarction (AMI).

We analyzed 101 patients with AMI and 377 controls for a potential correlation of the CYP2J2 polymorphism G-50T with a history of myocardial infarction. To evaluate the genotypes of the samples real time PCR with predesigned TaqMan SNP Genotyping Assays (Applied Biosystem) was used.

The allelic frequencies of CYP2J2^*1 and CYP2J2^*7 variants were 0.90 and 0.10 in the control group and 0.84 and 0.16 in the affected group, respectively.

Comparison of genotype and allele frequencies between patients and controls in the study of promoter located SNP CYP2J2^*7 did not provide a statistically significant association with AMI.

Our study found no association of the polymorphism in CYP2J2 with the development of AMI.